» Articles » PMID: 33680931

An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Mar 8
PMID 33680931
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is performed as curative-intent therapy for hematologic malignancies and non-malignant hematologic, immunological and metabolic disorders, however, its broader implementation is limited by high rates of transplantation-related complications and a 2-year mortality that approaches 50%. Robust reconstitution of a functioning innate and adaptive immune system is a critical contributor to good long-term patient outcomes, primarily to prevent and overcome post-transplantation infectious complications and ensure adequate graft-versus-leukemia effects. There is increasing evidence that unconventional T cells may have an important immunomodulatory role after allo-HCT, which may be at least partially dependent on the post-transplantation intestinal microbiome. Here we discuss the role of immune reconstitution in allo-HCT outcome, focusing on unconventional T cells, specifically mucosal-associated invariant T (MAIT) cells, γδ (gd) T cells, and invariant NK T (iNKT) cells. We provide an overview of the mechanistic preclinical and associative clinical studies that have been performed. We also discuss the emerging role of the intestinal microbiome with regard to hematopoietic function and overall immune reconstitution.

Citing Articles

Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.

Azhar Ud Din M, Lin Y, Lyu C, Yi C, Fang A, Mao F Mol Med. 2025; 31(1):2.

PMID: 39754054 PMC: 11699782. DOI: 10.1186/s10020-024-01060-x.


Comparison of oral zinc supplement and placebo effect in improving the T-cells regeneration in patients undergoing autologous hematopoietic stem cell transplantation: Clinical trial study.

Nikoonezhad M, Zavaran Hosseini A, Hajifathali A, Parkhideh S, Shadnoush M, Shakiba Y Medicine (Baltimore). 2024; 103(51):e33170.

PMID: 39705427 PMC: 11666199. DOI: 10.1097/MD.0000000000033170.


Unconventional T Cells Influence Clinical Outcome After Allogeneic Hematopoietic Cell Transplantation.

Siblany L, Stocker N, Ricard L, Brissot E, Dulery R, Banet A J Clin Immunol. 2024; 44(6):139.

PMID: 38822857 DOI: 10.1007/s10875-024-01741-6.


MAIT cells and the microbiome.

Jabeen M, Hinks T Front Immunol. 2023; 14:1127588.

PMID: 36911683 PMC: 9995591. DOI: 10.3389/fimmu.2023.1127588.


Selective depletion of naïve T cells by targeting CD45RA.

Naik S, Triplett B Front Oncol. 2023; 12:1009143.

PMID: 36776371 PMC: 9911795. DOI: 10.3389/fonc.2022.1009143.


References
1.
Correia D, Lopes A, Silva-Santos B . Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology. 2013; 2(1):e22892. PMC: 3583939. DOI: 10.4161/onci.22892. View

2.
DSouza A, Fretham C, Lee S, Arora M, Brunner J, Chhabra S . Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26(8):e177-e182. PMC: 7404814. DOI: 10.1016/j.bbmt.2020.04.013. View

3.
Minculescu L, Marquart H, Ryder L, Andersen N, Schjoedt I, Friis L . Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. Front Immunol. 2019; 10:1997. PMC: 6714591. DOI: 10.3389/fimmu.2019.01997. View

4.
Kuwatani M, Ikarashi Y, Iizuka A, Kawakami C, Quinn G, Heike Y . Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells. Immunol Lett. 2006; 106(1):82-90. DOI: 10.1016/j.imlet.2006.05.001. View

5.
Gaballa A, Stikvoort A, Onfelt B, Mattsson J, Sundin M, Watz E . T-cell frequencies of CD8 γδ and CD27 γδ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019; 54(10):1562-1574. DOI: 10.1038/s41409-019-0462-z. View